Basic Information
LncRNA/CircRNA Name | ANRIL |
Synonyms | NA |
Region | GRCh38_9:21994778-22121097 |
Ensemble | ENSG00000240498 |
Refseq | NR_003529 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | osteosarcoma |
ICD-0-3 | NA |
Methods | qPCR, Luciferase reporter assay, Western blot |
Sample | osteosarcoma cell lines |
Expression Pattern | differential expression |
Function Description | In this study, ANRIL shRNA was used to knock down its endogenous expression in U2-OS and Saos-2 osteosarcoma cell lines. Our data showed that ANRIL-silenced cells were more sensitive to cisplatin: apoptotic ratio was increased and cleaved caspase-3 level was upregulated. Furthermore, the expression level of miR-125a-5p, a microRNA that can bind to ANRIL, was elevated in ANRIL-silenced cells. |
Pubmed ID | 30777616 |
Year | 2019 |
Title | Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro. |
External Links
Links for ANRIL | GenBank HGNC NONCODE |
Links for osteosarcoma | OMIM COSMIC |